• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Anakinra not linked to reduction in fatigue severity in women with chronic fatigue syndrome

byDeepti Shroff KarhadeandEvelyn Nguyen
March 22, 2017
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a randomized, placebo-controlled trial of 50 women aged 18 to 59 years with chronic fatigue syndrome (CFS), the anti-inflammatory drug anakinra was not shown to have a clinically significant reduction in fatigue severity.

2. No differences of clinical importance or statistical significance were found in impairment level, pain severity, psychological distress, or physical and social functioning between the anakinra and placebo groups.

Evidence Rating Level: 2 (Good)

Study Rundown: Patients with chronic fatigue syndrome suffer from fatigue that is severe and disabling. Some evidence suggests that interleukin-1 (IL-1), a proinflammatory cytokine, may be involved in the pathogenesis of CFS. Anakinra is an IL-1 receptor antagonist capable of blocking both IL-1α and IL-1β. In a randomized, placebo-controlled trial of 50 women aged 18 to 59 years with CFS, participants were randomly assigned to placebo or daily subcutaneous anakinra (100 mg/d) for 4 weeks, followed by 20 additional weeks of tracking. Fatigue severity was the main outcome analyzed. Secondary outcomes included impairment level, pain severity, psychological distress, and physical and social functioning at 4 and 24 weeks. No differences of clinical importance or statistical significance were found for any measured outcomes. The authors propose that the findings could be the result of anakinra not reaching the brain in adequate concentrations when administered peripherally. The lack of effect could also be due to IL-1 having a limited role in CFS. The authors suggest that future studies regarding the possible role of IL-1 focus on intracerebral processes.

Strengths of the study include randomization of the patients to the placebo or anakinra group as well as blinding of providers, patients, and researchers regarding which treatment was assigned. Limitations of the study include a small sample size and heterogeneity in symptom duration.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Interleukin-1 as a mediator of fatigue in disease: a narrative review

RELATED REPORTS

In phase 3 trial, rituximab not associated with clinical improvement in patients with Myalgic encephalomyelitis/chronic fatigue syndrome

Insufficient evidence for treatments of myalgic encephalomyelitis/chronic fatigue syndrome

In-Depth [randomized controlled trial]: At the Department of Internal Medicine and the Expert Centre for Chronic Fatigue of Radboud University Medical Centre in the Netherlands, researchers randomly assigned 50 women aged 18 to 59 years with CFS to placebo (n = 25) or 100mg per day of subcutaneous anakinra (n = 25) for 4 weeks, with an additional 20 weeks of tracking for both groups. They study took place from July 2014 to May 2016. Providers, patients, and researchers were blinded to which treatment was assigned. Patients were taught how to perform the subcutaneous injection and were observed giving the first self-injection. All remaining doses were also self-administered. The Checklist Individual Strength subscale (CIS-fatigue) was used to measure fatigue severity at 4 weeks. The mean difference of 1.5 points (95%CI -4.1 to 7.2 points) between the two groups for fatigue severity and the measurements of secondary outcomes including impairment level, pain severity, psychological distress, and physical and social functioning at 4 and 24 weeks were not clinically or statistically significant. There were more injection site reactions in the anakinra group (68%) than the placebo group (4%).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic fatigue syndrome
Previous Post

Medical use of prescription opioids linked to nonmedical use in adolescents

Next Post

Family satisfaction with inpatient pediatric care varies widely between hospitals

RelatedReports

Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Chronic Disease

In phase 3 trial, rituximab not associated with clinical improvement in patients with Myalgic encephalomyelitis/chronic fatigue syndrome

April 5, 2019
Unclear if medical therapy management improves health outcomes
Chronic Disease

Insufficient evidence for treatments of myalgic encephalomyelitis/chronic fatigue syndrome

June 16, 2015
Next Post
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Family satisfaction with inpatient pediatric care varies widely between hospitals

Recurrent hemoptysis is effectively treated by bronchial artery embolization

Canadians with cystic fibrosis have a significant survival advantage over American patients

Low circulating cholesterol in neonates linked with pyloric stenosis

2 Minute Medicine Rewind March 20, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.